Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of LDL Cholesterol in Patients Switched From 10 to 5 Milligrams of Zetia (Ezetimibe)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects receiving ezetimibe 10 mg~* Subjects who have demonstrated compliance with ezetimibe as evidenced by the following Proportions of Days Covered patterns (which represent a PDC of more than 75%):~  * 90 day prescriptions: Filled a ezetimibe prescription within the previous 4 months~ * 60 day prescriptions: Filled a ezetimibe prescription within the previous 2.5 months~ * 30 day prescriptions: Filled a ezetimibe prescription within the previous 1.5 months~* Patients willing and able to provide signed informed consent~Exclusion Criteria:~* Patients not receiving ezetimibe~* Patients receiving ezetimibe 5 milligrams~* Patients with a history of being titrated from ezetimibe 5 to 10 mg. Stroke,TIA, myocardial infarction, unstable angina, percutaneous coronary intervention, coronary artery bypass surgery, or major surgery within the 3 months~* Cancer undergoing active treatment~* Participation in any clinical study within the last 30 days~* Drug addiction or alcohol abuse within the past 6 months~* Patients unwilling or unable to provide informed consent~* Patients with poor compliance~* Women of childbearing potential

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ezetimibe 10 mg (Type: ACTIVE_COMPARATOR): A whole ezetimibe 10 mg tablet
- Ezetimibe 5 mg (Type: EXPERIMENTAL): Ezetimibe 5 mg, formulated by splitting a 10 mg ezetimibe tablet in half

Based on this trial design, predict the completion outcome and termination type (if applicable).